S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
NASDAQ:BBIO

BridgeBio Pharma (BBIO) Stock Price, News & Analysis

$24.74
-0.21 (-0.84%)
(As of 04/19/2024 ET)
Today's Range
$24.27
$25.36
50-Day Range
$24.74
$39.23
52-Week Range
$12.75
$44.32
Volume
2.30 million shs
Average Volume
1.46 million shs
Market Capitalization
$4.35 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.82

BridgeBio Pharma MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
93.3% Upside
$47.82 Price Target
Short Interest
Bearish
10.29% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.31
Upright™ Environmental Score
News Sentiment
0.58mentions of BridgeBio Pharma in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$85,000 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.09) to ($2.76) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.43 out of 5 stars

Medical Sector

84th out of 909 stocks

Pharmaceutical Preparations Industry

28th out of 427 stocks

BBIO stock logo

About BridgeBio Pharma Stock (NASDAQ:BBIO)

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

BBIO Stock Price History

BBIO Stock News Headlines

BridgeBio Pharma Inc (BBIO)
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Short Interest Update
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
BridgeBio Pharma (NASDAQ:BBIO) Stock Price Down 5.7%
BridgeBio Pharma, Inc. (BBIO)
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
BBIO Mar 2024 32.000 call
BBIO Mar 2024 30.000 call
BBIO Mar 2024 30.000 put
BBIO Mar 2024 25.000 put
BBIO Mar 2024 31.000 call
BBIO Mar 2024 25.000 call
BridgeBio prices $250M stock offering
BridgeBio Pharma Prices Offering Of $250 Mln Of Shares
BBIO Mar 2024 31.000 put
See More Headlines
Receive BBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BridgeBio Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
4/21/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BBIO
Fax
N/A
Employees
550
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$47.82
High Stock Price Target
$70.00
Low Stock Price Target
$33.00
Potential Upside/Downside
+93.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
10 Analysts

Profitability

Net Income
$-643,200,000.00
Net Margins
-6,913.92%
Pretax Margin
-7,021.94%

Debt

Sales & Book Value

Annual Sales
$9.30 million
Book Value
($7.72) per share

Miscellaneous

Free Float
125,685,000
Market Cap
$4.35 billion
Optionable
Optionable
Beta
1.03
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Neil Kumar Ph.D. (Age 45)
    Co-Founder, President, CEO & Director
    Comp: $2.1M
  • Dr. Charles J. Homcy M.D. (Age 76)
    Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director
    Comp: $208k
  • Dr. Brian C. Stephenson C.F.A. (Age 43)
    Ph.D., CFO & Secretary
    Comp: $1.15M
  • Dr. Richard H. Scheller Ph.D. (Age 71)
    Chairman of Research & Development
    Comp: $202.4k
  • Dr. Frank P. McCormick Ph.D. (Age 74)
    Co-Founder, Chairman of Oncology & Director
  • Dr. Uma Sinha Ph.D. (Age 66)
    Chief Scientific Officer
    Comp: $1.31M
  • Grace Rauh
    Vice President of Communications
  • Mr. Eli M. Wallace Ph.D. (Age 57)
    Chief Scientific Officer of Oncology
  • Dr. Thomas Trimarchi Ph.D.
    Chief Product Officer
  • Dr. Eric Michael David J.D. (Age 52)
    M.D., Ph.D., Chief Executive Officer of Gene Therapy

BBIO Stock Analysis - Frequently Asked Questions

Should I buy or sell BridgeBio Pharma stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BridgeBio Pharma in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BBIO shares.
View BBIO analyst ratings
or view top-rated stocks.

What is BridgeBio Pharma's stock price target for 2024?

10 brokers have issued twelve-month price targets for BridgeBio Pharma's shares. Their BBIO share price targets range from $33.00 to $70.00. On average, they anticipate the company's stock price to reach $47.82 in the next year. This suggests a possible upside of 93.3% from the stock's current price.
View analysts price targets for BBIO
or view top-rated stocks among Wall Street analysts.

How have BBIO shares performed in 2024?

BridgeBio Pharma's stock was trading at $40.37 on January 1st, 2024. Since then, BBIO stock has decreased by 38.7% and is now trading at $24.74.
View the best growth stocks for 2024 here
.

Are investors shorting BridgeBio Pharma?

BridgeBio Pharma saw a increase in short interest in March. As of March 31st, there was short interest totaling 14,280,000 shares, an increase of 6.5% from the March 15th total of 13,410,000 shares. Based on an average daily volume of 1,730,000 shares, the days-to-cover ratio is presently 8.3 days. Currently, 10.3% of the shares of the stock are short sold.
View BridgeBio Pharma's Short Interest
.

When is BridgeBio Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our BBIO earnings forecast
.

How were BridgeBio Pharma's earnings last quarter?

BridgeBio Pharma, Inc. (NASDAQ:BBIO) announced its quarterly earnings results on Thursday, February, 22nd. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by $0.09. The company earned $1.74 million during the quarter, compared to analysts' expectations of $4.78 million. The company's revenue was down 8.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.92) earnings per share.

What other stocks do shareholders of BridgeBio Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BridgeBio Pharma investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Pfizer (PFE), Roku (ROKU), Editas Medicine (EDIT), Block (SQ), Sorrento Therapeutics (SRNE) and Sarepta Therapeutics (SRPT).

When did BridgeBio Pharma IPO?

BridgeBio Pharma (BBIO) raised $225 million in an initial public offering on Thursday, June 27th 2019. The company issued 15,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, Jefferies, SVB Leerink and KKR served as the underwriters for the IPO and Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James were co-managers.

Who are BridgeBio Pharma's major shareholders?

BridgeBio Pharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Portman Square Capital LLP (0.00%), Hennion & Walsh Asset Management Inc. (0.08%), Diversified Trust Co (0.02%), First Bank & Trust (0.00%) and Handelsinvest Investeringsforvaltning (0.00%). Insiders that own company stock include Brian C Stephenson, Douglas A Dachille, Frank Mccormick, Global Investors Lp Viking, Hannah Valantine, Neil Kumar, Randal W Scott, Richard H Scheller and Ronald J Daniels.
View institutional ownership trends
.

How do I buy shares of BridgeBio Pharma?

Shares of BBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BBIO) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners